Key Takeaways: Testosterone is the primary hormone driving sexual desire in women. Multiple large clinical trials confirm that testosterone therapy significantly improves libido, arousal, orgasm, and satisfaction in postmenopausal women with HSDD. The 2019 Davis meta-analysis (36 RCTs, 8,000+ women) found robust improvements with a favorable safety profile. Despite this evidence, no FDA-approved testosterone product for women exists in the US.
Testosterone: The Libido Hormone
In popular understanding, estrogen is the "female sex hormone" and testosterone is the "male sex hormone." This framing is misleading, particularly when it comes to libido.
Testosterone is the primary driver of sexual desire in both men and women. Estrogen supports vaginal health, lubrication, and genital blood flow, but the desire -- the wanting -- is predominantly testosterone-driven. This has been consistently demonstrated in clinical research.
The androgen receptors responsible for sexual desire are concentrated in the brain's hypothalamus and limbic system. Testosterone activates these receptors, triggering the neurochemical cascade (dopamine, norepinephrine) that produces sexual interest, fantasy, and motivation to seek intimacy.
When testosterone levels decline -- as they do with aging, menopause, oophorectomy, or certain medications -- sexual desire often declines in parallel. This is not a relationship issue, a psychological problem, or a character flaw. It is a hormonal deficit with a biological mechanism.
The Clinical Evidence
The Davis 2019 Meta-Analysis
The most comprehensive evidence comes from a 2019 systematic review and meta-analysis published in the Lancet Diabetes and Endocrinology by Davis et al. This pooled data from 36 randomized, placebo-controlled trials involving over 8,000 women.
Key findings:
- Sexual desire: Significantly improved compared to placebo (standardized mean difference 0.36)
- Arousal: Significantly improved
- Orgasm: Significantly improved (both frequency and quality)
- Sexual satisfaction: Significantly improved
- Satisfying sexual events: Increased by approximately 1-2 per month over placebo
- Sexual distress: Significantly reduced
Safety findings:
- No significant increase in cardiovascular events
- No significant increase in breast cancer
- Acne and hair growth were more common but generally mild
- Weight and lipid profiles were not adversely affected
The strength of this meta-analysis lies in its scope: 36 trials, multiple countries, multiple delivery methods, consistent results across populations.
The Shifren 2006 Study
A landmark trial that helped establish the evidence base. Shifren et al. published results from a randomized, double-blind, placebo-controlled trial of testosterone patches in surgically menopausal women with HSDD.
Design: 562 women randomized to testosterone patch (300 mcg/day) or placebo for 24 weeks.
Results:
- Satisfying sexual events increased from 3.0 to 4.9 per month (vs 3.0 to 3.7 with placebo)
- Sexual desire score improved significantly
- Personal distress about sexual function decreased significantly
- The difference was clinically meaningful -- women noticed and valued the improvement
Side effects: Androgen-related side effects (acne, unwanted hair growth) were more common with testosterone but generally mild and manageable.
The ADORE Trial
The ADORE (Androgen in the Desire and Orgasmic Response) trial studied testosterone cream in naturally menopausal women with HSDD.
Key contributions:
- Demonstrated that testosterone cream (not just patches) effectively improves libido
- Showed benefits in naturally menopausal women (not just surgically menopausal)
- Confirmed that improvements in desire correlated with improvements in overall sexual function
- Established the 3-6 month timeframe for full effect
The APHRODITE Study
This multicenter trial evaluated the safety and efficacy of testosterone gel in postmenopausal women with HSDD.
Results:
- Significant improvement in satisfying sexual events
- Improvement in desire, arousal, and orgasm subscales
- Favorable safety profile over the study period
- Supported the use of testosterone gel as a delivery method
Understanding HSDD
Hypoactive Sexual Desire Disorder (HSDD) is the clinical term for persistent, distressing loss of sexual desire. It is the most common female sexual dysfunction, affecting an estimated 10% of women.
Diagnostic Criteria
HSDD requires both components:
- Persistently reduced or absent sexual desire (fantasies and/or desire for sexual activity) that was previously present
- Personal distress about the decrease in desire
The distress component is critical. Some women have low sexual desire and are not bothered by it. That is not HSDD. The disorder exists when the lack of desire causes personal suffering -- frustration, sadness, feelings of inadequacy, or relationship strain.
What HSDD Is Not
- Not a relationship problem (though relationship issues can coexist)
- Not a consequence of depression (though depression can cause low desire)
- Not a medication side effect (though SSRIs and other medications can reduce libido)
- Not normal aging (age-related desire decline that does not cause distress is not a disorder)
HSDD is diagnosed after excluding these other causes. If low desire persists after addressing relationship issues, depression, medication effects, and other medical conditions, testosterone deficiency becomes a primary suspect.
Prevalence
- Approximately 10% of women meet criteria for HSDD
- Prevalence increases with age: 7% in women 18-44, 12% in women 45-64
- Many more women have decreased desire without meeting full HSDD criteria
- The condition is significantly underdiagnosed because women are reluctant to raise it and clinicians rarely ask
The Libido Timeline on Testosterone
Understanding the typical progression helps set expectations and prevents premature discontinuation.
Weeks 1-2
- No significant change in desire for most women
- Testosterone levels are still reaching steady state
Weeks 3-4
- The earliest stirrings of improvement
- Some women notice fleeting sexual thoughts or subtle arousal responses
- "The pilot light is flickering back on"
Weeks 4-6
- More consistent improvement in sexual thoughts and desire
- Spontaneous interest in intimacy begins returning
- Arousal response to sexual stimuli improves
Weeks 6-12
- Desire becomes more reliable and noticeable
- Arousal and lubrication improve
- Orgasm quality and frequency begin improving
- Partners often notice the change
Month 3-6
- Full expression of libido improvement
- Sexual function stabilizes at the new, improved baseline
- Orgasm intensity and frequency continue to optimize
- Overall sexual satisfaction reaches its peak benefit
Month 6+
- Maintained improvement as long as treatment continues
- The 6-month assessment per Global Consensus guidelines should confirm benefit
- Desire does not typically continue increasing beyond this point but sustains
The FDA Landscape
Despite robust clinical evidence, there is no FDA-approved testosterone product for women in the United States. This is not because the evidence is insufficient. It reflects regulatory and commercial challenges.
Historical Attempts
Intrinsa (testosterone patch): Procter and Gamble's testosterone patch for women was approved in Europe in 2006 but was rejected by the FDA. The FDA advisory panel voted 14-3 against approval, citing concerns about long-term cardiovascular and breast cancer safety data -- despite no adverse signals in trials up to that point.
LibiGel (testosterone gel): BioSante Pharmaceuticals conducted Phase III trials of a testosterone gel for women. The trial was terminated in 2012 due to an independent safety monitoring board's recommendation, though the specific safety concern was never publicly detailed.
Why No Approval
Several factors contribute:
-
Long-term safety data requirements: The FDA wants safety data spanning years, but clinical trials are typically 6-24 months. No company has been willing to fund a multi-year trial for a low-cost, compoundable hormone.
-
Difficulty demonstrating benefit in "subjective" outcomes: Sexual desire is measured by patient-reported questionnaires, which some regulators view as less robust than "hard" endpoints like blood pressure or fracture rates.
-
Commercial viability: Testosterone is an inexpensive, generic compound that can be compounded. The return on investment for an FDA approval process (costing $100M+) is uncertain.
-
Regulatory conservatism: After the Women's Health Initiative fallout regarding estrogen and progesterone, the FDA has been cautious about approving any hormonal therapy for women.
The Current Reality
Women in the US access testosterone through:
- Compounding pharmacies -- the most common route, using prescriptions written by knowledgeable clinicians
- Off-label use of male products -- some clinicians prescribe low doses of commercial testosterone preparations
- Specialty telehealth platforms -- emerging services that prescribe and ship compounded testosterone for women (compare options in our clinic comparison)
In Australia, Andriol (oral testosterone undecanoate) is available. In Europe, Intrinsa was available but was voluntarily withdrawn for commercial reasons. Several countries are ahead of the US in recognizing testosterone's role in female health.
Beyond Libido: Other Sexual Function Benefits
Testosterone improves more than just desire:
Arousal
- Genital blood flow increases in response to sexual stimuli
- Lubrication improves (both genital and vaginal)
- Physical arousal matches psychological desire more closely
Orgasm
- Orgasm frequency increases
- Orgasm intensity improves
- Time to orgasm may decrease
- Some women who had become anorgasmic regain orgasmic function
Satisfaction
- Overall satisfaction with sexual encounters improves
- Personal distress about sexual function decreases
- Relationship satisfaction often improves as a secondary effect
Sensitivity
- Clitoral sensitivity may increase (a positive effect at physiological doses)
- Genital responsiveness to touch improves
- Some women report that sexual pleasure becomes more vivid and intense
When Testosterone Is Not the Answer
Not all low libido in women is testosterone-related. Consider these before or alongside testosterone:
- Relationship issues -- unresolved conflict, emotional disconnection, or mismatched desire
- Depression and anxiety -- directly suppress desire through neurotransmitter mechanisms
- Medications -- SSRIs, oral contraceptives, and anti-hypertensives can all reduce libido
- Pain conditions -- vulvodynia, endometriosis, or dyspareunia make sex aversive
- Body image -- severe body dissatisfaction can suppress desire regardless of hormones
- Stress and sleep deprivation -- cortisol elevation suppresses sexual function
- Thyroid dysfunction -- both hypo- and hyperthyroidism affect libido
The best outcomes occur when testosterone is used as part of a comprehensive approach that addresses all contributing factors. A knowledgeable provider will evaluate the full picture before starting treatment -- see our clinic comparison.
Related Reading
This content is for informational purposes only and is not medical advice. Consult a qualified healthcare provider before starting any treatment.